Agent
BOLD names are
FDA approved agents
|
B or T cell
|
Target
of Drug
|
Approved
Indication
|
Queries Locate
Studies on
ClinicalTrials.gov
|
Counting
Clicks
as of
3/7/13
4,651 |
Find
Clinical Reports
on Agent
Google
Scholar
|
Monoclonal antibodies
(Mab)
See
also
Immune
mediated
Monoclonal antibodies (MAbs)
are similar to antibodies produced by
the body in response to infection. MAbs bind to specific
receptor expressed on the tumor and some normal cells.
|
|
Agent
Click to search for
mechanism of action |
|
Target |
|
Find Trials |
Count
|
Clinical Reports |
MEDI-551 (humanized
antibody)
|
B |
cd19 |
- |
Find trials
> |
44 |
Reports |
Arzerra ® (Ofatumumab)
|
B |
cd20 |
CLL |
Find trials
> |
183 |
Reports |
Rituxan
®
(Rituximab / Mabthera)
|
B |
cd20 |
NHL |
Find trials
> |
70 |
Reports |
GA-101 (Obinutuzumab)
|
B |
cd20 |
- |
Find trials
> |
398 |
Reports |
Ublituximab
|
B |
cd20 |
- |
Find
trials
> |
18 |
|
Veltuzumab / Immu-106 / Ha20
|
B |
cd20 |
- |
Find trials
> |
11 |
Reports |
Epratuzumab
|
B |
cd22 |
- |
Find trials
> |
84 |
Reports |
Lumiliximab
|
B |
cd23 |
- |
Find trials
> |
40 |
Reports |
SGN-30
|
B / T |
cd30 |
- |
Find trials
> |
53 |
Reports |
TRU-016
|
B |
cd37 |
- |
Find trials
> |
72 |
Reports |
Zanolimumab
|
T |
cd4 |
- |
Find trials
> |
53 |
Reports |
Campath ® (alemtuzumab)
|
B |
cd52 |
CLL |
Find trials
> |
33 |
Reports |
MDX-1411
|
B / T |
cd70 |
- |
Find trials
>
|
50 |
Reports |
Milatuzumab / hLL1
|
B |
cd74 |
- |
Find trials
> |
50 |
Reports |
IMMU-114 (anti-HLA-DR)
|
|
HLA-DR |
- |
Find trials
> |
1 |
Reports |
Mogamulizumab
(Mogo)
(KW-0761; AMG-761)
|
T |
CCR4 |
- |
Find trials
> |
45 |
Reports
PAL |
Bispecific antibodies
Binding two receptors
expressed on tumor cells and/or other immune cells
|
|
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
DT2219ARL
anti-CD19/22 Bispecific
antibody + immunotoxin
|
B |
cd19 cd22 |
Initial
count:
72
> |
Find
trials
>
|
85 |
Reports |
Blinatumomab / MT103
/ BiTe)
|
B |
cd3 cd19 |
- |
Find trials
>
|
94 |
Reports |
antibody-drug conjugates
Uses antibodies to
delivers toxins to cells that have a specific target receptor
|
 |
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
SGN-CD19A
anti-CD19
+ toxin
|
B |
cd19 |
NEW |
Find trials
>
|
3 |
Reports |
SAR3419
anti-CD19
+ maytansinoi
|
B |
cd19 |
- |
Find trials
>
|
104 |
Reports |
DT2219ARL
anti-CD19 & 22
antibody + immunotoxin
|
B |
cd19 cd22 |
- |
Find trials
>
|
100 |
Reports |
Inotuzumab Ozogamicin
anti-CD22
+ calicheamicin
|
B |
cd22 |
- |
Find trials
>
|
206 |
Reports |
DCDT2980S
anti-CD22,
conjugated to MMAE
|
B |
cd22 |
- |
Find trials
>
|
18 |
Reports |
LMB-2 immunotoxin
anti-CD25 antibody
+ immunotoxin
|
B |
cd25 |
- |
Find trials
>
|
28 |
Reports |
Adcetris ®
(SGN-35 / brentuximab vedotin)
anti-cd30
+ antitubulin
|
B/T |
cd30 |
HL / ALCL |
Find trials
> |
178 |
Reports
Technical - PK / dosing |
Radio-immunotherapy
Uses antibodies to delivers
radiation to cells in a targeted way
|
 |
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
Betalutin
|
B |
cd37 |
NHL |
Find trials
> |
NEW |
Reports |
Bexxar
®
anti-CD20 +
iodine 131 (Tositumomab,
Iodine I 131)
|
B |
cd20 |
NHL |
Find trials
>
|
63 |
Reports |
Zevalin
®
anti-CD20 +
Yttrium 90 (Ibritumomab tiuxetan)
|
B |
cd20 |
NHL |
Find trials
>
|
79 |
Reports |
epratuzumab tetraxetan
anti-CD22 with fractionated Yttrium 90
|
B |
cd22 |
- |
Find trials
>
|
63 |
Reports |
Immune-mediated
Immune
mediated therapy assists in helping
the immune system to attack the tumor.
See
also antibody agents, and radioimmunotherapy, which may also
be immune-mediated
|
 |
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
|
Anti-PD-1 antibody
pidilizumab (CT-011)
OR
BMS-936558 (nivolumab)
(Immune checkpoint blockade)
|
B |
PD-1 (P7) |
Initial
count:
195
> |
Find trials
> |
Total
272 |
Reports |
|
ipilimumab
anti-CTL-A
(MXD-010)
(Immune checkpoint blockade)
|
B |
CTL-A
t-reg |
- |
Find trials
>
|
15 |
Reports |
|
immunocytokine
therapy
composed of two immune components – antibodies and
cytokines
|
- |
- |
- |
Find trials
>
|
6 |
Reports |
|
Revlimid ® / Lenalidomide
/ CC
5013
(Immune
modulating / cereblon)
|
- |
unknown |
MDS / myeloma |
Find trials
>
|
95 |
Reports |
Lenalidomide AND Rituxan
|
- |
unknown + cd20 |
New combination |
Find trials
>
|
4
|
Reports |
|
Pomalidomide
(Immune
modulating)
|
- |
unknown |
NEW |
Find trials
>
|
5 |
Reports |
T-cell therapy
(adoptive
immunotherapy)
|
B or T |
- |
- |
Find trials
>
|
14 |
|
|
cd19 CAR T-cell therapy
(CAR - chimeric antigen
receptor)
(adoptive
immunotherapy)
|
B |
cd19 |
Initial
count:
148
> |
Find trials
> |
184
|
Reports
About by PAL |
|
Vaccine
(idiotype) therapy
|
B |
tumor antigen |
- |
Find trials for agent
>
|
32 |
Reports |
Cytotoxic Agents
Damage the DNA of rapidly dividing cells,
triggering apoptosis (programmed cell death)
|
|
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
Treanda
®
(Bendamustine)
|
B or T |
DNA |
NHL/CLL |
Find trials
>
|
78 |
Reports |
Bendamustine
phase 3 trials
|
B or T |
DNA |
NHL/CLL |
Phase 3 trials
> |
25 |
Reports |
Folotyn ®
(Pralatrexate)
|
- |
DNA |
T-cell |
Find trials
>
|
6 |
Reports |
Pixantrone
|
B |
DNA |
- |
Find trials
> |
6 |
Reports |
Targeted Agents
|
|
|
Epigenetic Agents
Agents that modify gene
expression (by
methylation or acetylation of histones and other elements) can
reprogram how tumor cells behave: grow, die, or differentiate.
|
DNA
hypo/hyper-methylation
can
reactivate tumor suppressor genes by altering methylation
|
Hypermethylation-associated silencing of tumor suppressor
genes has been shown to occur in lymphoid/hematopoietic
malignancies, disrupting many cellular pathways.1-3
Unlike genetic alterations in cancer, hypermethylation
changes are potentially reversible by pharmacologic
inhibition of DNA methylation.4
The cytidine analogs 5-aza-2′-deoxycytidine and
5-azacytidine are capable of reactivating tumor suppressor
genes that were silenced by hypermethylation.4
|
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
Vidaza ®
(5-Azacytidine)
|
B |
DNA hypo-methylation |
initial
count: 19
> |
Find
trials
>
|
20 |
Reports |
HDAC inhibition
interferes with the function of histone deacetylase -
modifying gene expression
About by PAL
|
|
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
Abexinostat (PCI-24781)
|
|
HDAC |
|
Find trials
>
|
25 |
Reports |
Belinostat (PXD101)
|
T or B |
HDAC |
|
Find trials
> |
32
|
Reports |
Panobinostat
(LBH589)
|
T or B |
HDAC |
|
Find trials
> |
54 |
Reports |
Romidepsin
® (Depsipeptide)
|
T or B |
HDAC |
Approved for
T-cell lymphoma |
Find trials
> |
21 |
Reports |
Valproic acid
|
T or B |
HDAC |
AML / MDS |
Find trials
> |
78 |
Reports |
Zolinza
®
(Vorinostat)
|
T or B |
HDAC |
Approved for
T-cell lymphoma |
Find trials
>
|
87 |
Reports |
BCL-2 inhibitors
Binds to BCL-2 pathway involved
in the blocking of apoptosis (programmed cell death)
|
|
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
ABT-199
|
B |
bcl-2
pathway |
|
Find trials
> |
54 |
Reports
ASCO report |
Obatoclax mesylate / GX15-070)
|
B |
bcl-2
pathway |
- |
Find trials
> |
51 |
Reports |
mTOR
Binds the mTOR pathway that
promotes survival and cell growth
|
|
Agent
|
|
Target |
|
Find Trials |
Count |
Reports |
CC-223
dual mTOR inhibitor (oral)
|
B |
mTOR |
- |
Find trials
> |
21 |
Reports |
Everolimus
/ RAD001 (oral)
|
B |
mTOR |
- |
Find trials
> |
52 |
Reports |
Temsirolimus
/ CCI-779 (IV)
|
B |
mTOR |
- |
Find trials
> |
38 |
Reports |
Kinase inhibitors
Inhibit
transcription pathways that are overactive in cancer
|
|
|
|
|
Target |
|
Find Trials |
Count |
Reports |
AEB071 (Sotrastaurin)
|
subtype
of DLBCL |
Protein Kinase C Inhibitor |
|
Find trials
> |
NEW |
Report |
|
T |
Aurora Kinase A |
t-cell
lymphoma |
Find trials
> |
23 |
Reports |
AVL-292
|
B |
Bruton's tyrosine (Btk) |
- |
Find trials
> |
70 |
Reports |
Idelalisib /
GS-1101
(formerly CAL101)
|
B |
PI3k delta |
CLL and NHL |
Find trials
> |
438 |
Reports |
Ibrutinib
(PCI-32765)
|
B |
Bruton's
tyrosine (Btk) |
FDA breakthrough designation |
Find trials
> |
396 |
Reports
About
by PAL |
Ibrutinib for
CLL -Open Studies Only
|
- |
- |
- |
Find trials
> |
NEW |
- |
IPI-145
|
B or T |
(PI3K)-delta and PI3K-gamma |
|
Find trials
> |
NEW |
Reports |
Other targeted
agents
|
|
|
|
|
Target |
|
Find Trials |
Count |
Reports |
PD 0332991
|
|
Cdk |
- |
Find trials
> |
19 |
Reports |
ISIS 481464 (AZD9150)
antisense oligonucleotide
inhibitor of STAT3
|
|
STAT3 |
|
Find trial
> |
NEW |
Report |
YM155
|
B |
survivin kinase |
- |
Find trials
> |
61 |
Reports |
proteasome inhibitors
MLN970 / Bortezomib /
Velcade
® ,
Carfilzomib,
CEP 18770
|
|
proteasome inhibitors |
- |
Find trials
> |
10 |
Reports |
TL32711
|
|
inhibitors of
apoptosis |
|
Find trials
> |
8 |
Reports |
Discontinued agents
|
|
Enzastaurin
|
B |
C-beta |
- |
Find trials
> |
25 |
Reports |
Navitoclax
/ ABT-263
>
Discontinued due to improvement in safety with ABT-199 above
|
B |
bcl-2
pathway |
- |
http://bit.ly/5fcv13
|
99 |
Reports |
|
|
|
|
|
|
|
|